Analysts Set Pulmonx Co. (NASDAQ:LUNG) PT at $12.75

Pulmonx Co. (NASDAQ:LUNG) has received an average rating of “Moderate Buy” from the six analysts that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $12.75.

A number of research analysts recently commented on LUNG shares. Wells Fargo & Company lowered their price target on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a report on Wednesday, December 11th. Citigroup reaffirmed a “neutral” rating and issued a $7.50 price target (down previously from $17.00) on shares of Pulmonx in a report on Wednesday, December 11th.

Pulmonx Stock Up 0.5 %

Shares of NASDAQ:LUNG opened at $7.48 on Monday. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. Pulmonx has a 12 month low of $5.46 and a 12 month high of $10.01. The company has a 50-day moving average price of $6.95 and a 200 day moving average price of $6.94. The company has a market cap of $297.67 million, a price-to-earnings ratio of -5.19 and a beta of 0.50.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings results on Wednesday, February 19th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.12. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. The firm had revenue of $23.77 million during the quarter, compared to the consensus estimate of $22.29 million. As a group, equities research analysts predict that Pulmonx will post -1.55 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Glendon E. French III sold 55,453 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $8.28, for a total transaction of $459,150.84. Following the transaction, the director now directly owns 1,011,974 shares of the company’s stock, valued at approximately $8,379,144.72. This trade represents a 5.20 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Geoffrey Beran Rose sold 5,779 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $7.13, for a total transaction of $41,204.27. Following the transaction, the insider now directly owns 285,278 shares in the company, valued at approximately $2,034,032.14. This trade represents a 1.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 127,986 shares of company stock valued at $986,673 in the last ninety days. 5.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Pulmonx

A number of institutional investors have recently modified their holdings of LUNG. GSA Capital Partners LLP purchased a new position in shares of Pulmonx during the third quarter worth approximately $537,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Pulmonx during the third quarter worth approximately $480,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in Pulmonx by 5.2% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,114,297 shares of the company’s stock valued at $9,238,000 after buying an additional 55,279 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Pulmonx by 5.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 313,169 shares of the company’s stock valued at $2,596,000 after buying an additional 15,543 shares during the period. Finally, FMR LLC increased its holdings in Pulmonx by 11.2% during the third quarter. FMR LLC now owns 5,872,882 shares of the company’s stock valued at $48,686,000 after buying an additional 591,859 shares during the period. 91.04% of the stock is owned by hedge funds and other institutional investors.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.